Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive. The Nanoform team reviews solid form strategies for increasing the solubility and oral bioavailability of small molecule drugs.
Christian Jones, CCO of Nanoform, discusses what it truly means to be patient-centric in the modern pharmaceutical industry. Dive into the challenges pharma companies are facing as they switch focus, as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Explore new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
Discover how Nanoform’s revolutionary and environmentally sustainable nanoparticle technologies coupled with its innovative formulation approaches, can not only address drug solubility issues but also add value for patients in novel drug delivery applications.
Nanoforming services provide solutions to complex formulation challenges, such as low drug compound solubility and drug delivery routes. Find the nanoparticle engineering, formulation, and GMP manufacturing services that can drive forward your market success and unlock the power of “small."
